Join
Live feed
·
PRReleasevia Quantisnow
Verastem Inc. logo

Verastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, Enabling Phase 1/2a Trial in Advanced Solid Tumors

ByQuantisnow·Wall Street's wire, on your screen.
VSTM· Verastem Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track VSTM (Verastem Inc.) and more on Quantisnow.